1. VI-14, a novel flavonoid derivative, inhibits migration and invasion of human breast cancer cells
- Author
-
Li, Fanni, Li, Chenglin, Zhang, Haiwei, Lu, Zhijian, Li, Zhiyu, You, Qidong, Lu, Na, and Guo, Qinglong
- Subjects
- *
FLAVONOIDS , *CELL migration inhibition , *BREAST cancer , *CANCER cells , *APOPTOSIS , *NEOVASCULARIZATION , *METASTASIS , *CELL adhesion inhibition , *MATRIX metalloproteinases - Abstract
Abstract: It has been well characterized that flavonoids possess pronounced anticancer potentials including anti-angiogenesis, anti-metastasis, and pro-apoptosis. Herein, we report, for the first time, that VI-14, a novel flavonoid derivative, possesses anti-cancer properties. The purpose of this study is to investigate the anti-migration and anti-invasion activities of VI-14 in breast cancer cells. Our data indicate that VI-14 inhibits adhesion, migration and invasion of MDA-MB-231 and MDA-MB-435 human breast cancer cells. MDA-MB-231 cells treated with VI-14 display reduced activities and expressions of ECM degradation-associated proteins including matrix metalloproteinase 2 (MMP-2) and 9 (MMP-9) at both the protein and mRNA levels. Meanwhile, VI-14 treatment induces an up-regulated expression of tissue inhibitor of metalloproteinase 1 (TIMP-1) and 2 (TIMP-2) in MDA-MB-231 cells. Western blotting results show that phosphorylation levels of critical components of the MAPK signaling pathway, including ERK, JNK and P38, are dramatically decreased in VI-14-treated MDA-MB-231 cells. Furthermore, treatment of VI-14 significantly decreases the nuclear levels and the binding ability of nuclear factor-kappa B (NF-κB) and activator protein-1 (AP-1). Taken together, our data suggest that VI-14 treatment suppresses migration and motility of breast cancer cells, and VI-14 may be a potential compound for cancer therapy. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF